SOUTH SAN FRANCISCO, CA--(Marketwire - October 20, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society, which was held October 16-18, 2008 at the Hotel Pacific Tokyo in Tokyo, Japan. These data represent an interim analysis of results in an ongoing Phase IIa clinical trial evaluating CK-1827452 in stable heart failure patients. CK-1827452 is a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure.
